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Abstract
Background: Epigenetic aberrations play a central role in the pathophysiology of acute myeloid leukemia (AML).
It has been shown that molecular signatures based on DNA-methylation (DNAm) patterns can be used for
classification of the disease. In this study, we followed the hypothesis that DNAm at a single CpG site might
support risk stratification in AML.
Findings: Using DNAm profiles of 194 patients from The Cancer Genome Atlas (TCGA), we identified a CpG site
in complement component 1 subcomponent R (C1R) as best suited biomarker: patients with higher methylation
at this CpG site (>27 % DNAm) reveal significantly longer overall survival (53 versus 11 months; P < 0.0001). This
finding was validated in an independent set of 62 DNAm profiles of cytogenetically normal AML patients (P = 0.009)
and with a region-specific pyrosequencing assay in 84 AML samples (P = 0.012). DNAm of C1R correlated with genomic
DNAm and gene expression patterns, whereas there was only moderate association with gene expression levels of C1R.
These results indicate that DNAm of C1R is a biomarker reflecting chromatin reorganization rather than being of
pathophysiological relevance per se. Notably, DNAm of C1R was associated with occurrence of specific genomic
mutations that are traditionally used for risk stratification in AML. Furthermore, DNAm of C1R correlates also with
overall survival in several other types of cancer, but the prognostic relevance was less pronounced than in AML.
Conclusions: Analysis of DNAm at C1R provides a simple, robust, and cost-effective biomarker to further complement
risk assessment in AML.
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Findings
Risk assessment is relevant for the choice of therapeutic
regimen in acute myeloid leukemia (AML). It is usually
based on many parameters including age, white blood cell
count, cytogenetic abnormalities, and specific mutations
[1]. Epigenetic modifications, such as DNA-methylation
(DNAm) changes, seem to play a critical role in pathogen-
esis of AML [2]. Various studies demonstrated that DNAm
patterns can discriminate subgroups of patients with
different clinical outcomes [3–7]. So far, these approaches
utilized a combination of many differentially methylated
regions and therefore require DNAm profiles based on
microarray or sequencing technology. In contrast, a
region-specific assay would be much faster, economic,
and easier to interpret. We have recently described that
aberrant hypermethylation at a specific region of the
de novo methyltransferase DNMT3A is associated with
poor prognosis in AML, but this association was only
significant for patients without genomic mutations in
DNMT3A because both modifications seem to have a
similar molecular and clinical sequel [8]. This exempli-
fies that identification of simple epigenetic markers is
hampered by the high molecular and clinical hetero-
geneity of the disease. Despite these hurdles, we
followed the hypothesis that DNAm at a unique CpG
site might provide a robust biomarker to further sup-
port risk assessment of AML.
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Selection of CpG sites that are indicative for overall
survival in AML
For initial selection of prognostic relevant CpGs, we uti-
lized 194 DNAm profiles of AML patients from The
Cancer Genome Atlas (TCGA) [9]. For each CpG site,
the samples were stratified by its median DNAm level to
estimate association with overall survival (OS) using the
Kaplan-Meier (K-M) method (Fig. 1a). Only 60 CpGs
revealed significant association upon adjustment for
multiple testing (adjusted P < 0.05; Fig. 1b). Alternatively,
we selected 418 CpGs with significant association with OS
by COX-regression analysis (adjusted P < 0.05; Additional
file 1: Figure S1). Only 26 CpGs were in the overlap of
K-M and COX analysis (Additional file 1: Table S1). To
narrow down to the best suited CpGs, we used the fol-
lowing additional criteria: (1) Sites should reveal rela-
tively high variation in DNAm across different AML
samples (as a higher DNAm range facilitates more reli-
able discrimination); (2) DNAm levels should be similar
in different types of blood cells (to avoid bias by blood
Fig. 1 DNA-methylation at C1R has prognostic relevance in AML. a Scheme for selection of the relevant CpG site. b For Kaplan-Meier (K-M) estimation
of overall survival (OS) in 194 AML patients, [9] the DNAm levels for each of the 390,000 CpGs were stratified by their median DNAm level. The
Manhattan plot demonstrates that the 60 CpGs with adjusted P < 0.05 (dashed line) are distributed over different chromosomes. c Beta-value
distribution at the CpG site cg08799922 (C1R) in 656 healthy controls (GSE40279) [19] and 194 AML samples (TCGA) [9]. d K-M plot of TCGA
samples classified by median DNAm level at cg08799922 (C1R; median DNAm level 27 %; P < 0.0001). e Beta-value distribution of DNAm in C1R
of 10 healthy controls and 62 cytogenetic normal AML (CN-AML) samples (GSE58477) [13]. f Validation of prognostic relevance of cg08799922 for OS in
this dataset (P< 0.009; classified by DNAm level of 27 %). g Beta-value distribution of DNAm in C1R of 40 healthy controls and 84 AML samples analyzed
by pyrosequencing. h K-M plot of these AML samples upon classification by 27 % DNAm level at the relevant CpG site in C1R (P< 0.012)
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counts) [10]; and (3) there should be no correlation with
age. In fact, many CpGs reveal age-associated DNAm
changes [11, 12] and age is a major confounding factor for
OS. Therefore, we excluded CpGs with clear DNAm
changes upon aging. Using these parameters, we identified
four candidate CpGs (Additional file 1: Table S1; Fig. 1c, d;
Additional file 1: Figures S1–S3), which were tested in an
independent dataset of Qu et al. [13]. Only one CpG site,
positioned in the 5’UTR of complement component 1
subcomponent R (C1R, cg08799922), revealed significant
association with OS (K-M analysis: P = 0.009; COX ana-
lysis: P = 0.012; Fig. 1e, f). We then designed a pyrose-
quencing assay for site-specific analysis at this genomic
location (Additional file 1: Figure S4). Pyrosequencing re-
sults of 84 AML patients were stratified by the threshold
of 27 % DNAm at cg08799922 (C1R), corresponding to
the median beta-value in the training set (TCGA).
Again, there was a clear association with OS (K-M analysis:
P = 0.012; COX analysis: P = 0.035; Fig. 1g, h).
Epigenetic co-regulation of C1R with other genomic
regions and correlation with gene expression
The serine protease C1R catalyzes the initial event of the
classical complement pathway, which is crucial for in-
nate defense mechanisms against pathogens and altered-
self cells [14]. The CpG site is located in the 5’UTR
region of C1R and may interfere with a CCCTC-binding
factor (CTCF) and cohesin-binding site (Fig. 2a) [15].
Differential DNAm in the neighboring genomic region is
of prognostic relevance too, as another upstream site of
cg08799922 was also among the initial 60 CpGs from the
K-M estimate (Fig. 2b; cg06915053, adjusted P = 0.047).
Furthermore, neighboring CpGs in the pyrosequencing
assay revealed similar correlation with OS as well (Add-
itional file 1: Figure S5). To determine whether or not
DNAm at C1R (cg08799922) was co-regulated with other
genomic regions, we performed linear correlation of
DNAm with all CpGs from the 450K BeadChip: 1448
CpGs correlated (Pearson’s R >0.5), and these were
particularly located in homeobox genes (Additional file 1:
Figure S6). This co-regulation of C1R and HOX regions
might be mediated by chromatin loops via CTCF and
cohesin [16]. Furthermore, we analyzed if higher methyla-
tion of C1R entails down-regulation of the corresponding
gene, but there was only a moderate association from
RNA-seq data (R = 0.35, Fig. 2c). However, expression
of 82 genes throughout the genome correlated with
DNAm in C1R and were linked to developmental pro-
cesses (R >0.5; Additional file 1: Figure S7). Taken to-
gether, DNAm of C1R does not seem to be relevant for
functional changes in AML per se; it rather resembles a
biomarker that reflects reorganization of chromatin in
a subset of AML patients.
Association of DNA-methylation at C1R with clinical
parameters
DNAm levels in C1R were subsequently compared with
clinical parameters of the TCGA dataset [9]: there was no
clear association with blast counts (R = 0.0046; Fig. 2d) and
no gender difference (Mann-Whitney P = 0.82; Fig. 2e).
AML samples with favorable cytogenetic risk score (Fig. 2f)
and AML subtype M3 (Fig. 2g) revealed significantly
higher DNAm in C1R. Multivariate analysis of OS consid-
ering age, gender, bone marrow blast count, and FAB clas-
sification demonstrated that DNAm at C1R can support
risk stratification (Additional file 1: Table S2). If alterna-
tively only DNAm in C1R, cytogenetic risk score, and
molecular risk score were included as parameters for
multivariate analysis, the relevance of C1R was also signifi-
cant (Additional file 1: Table S3). However, if all parameters
were combined into one multivariate model, only age and
molecular risk score were classified as relevant parameters
(Additional file 1: Table S4). To further evaluate if the
prognostic relevance of DNAm in C1R is independent
from cytogenetic risk groups, we performed K-M analysis
within individual cytogenetic groups. DNAm at C1R
revealed significant association with OS in the intermediate
group of TCGA (K-M analysis: P = 0.015), and the same
trend was also observed in the other groups (in TCGA and
pyrosequencing datasets; Additional file 1: Figure S8).
These results indicate that DNAm in C1R might be of
independent prognostic relevance, but this needs to be
further validated in larger cohorts. Furthermore, higher
methylation at C1R was associated with significantly less
mutations in TP53, RUNX1,TET2, and DNMT3A, whereas
mutations in CEBPA and WT1 and the translocations
PML-PARA and MYH11-CBFB were significantly enriched
(Fig. 2h; Additional file 1: Figure S9). Thus, it can be specu-
lated that either DNAm at C1R is influenced by these
mutations or vice versa [12, 17]. Because of the strong
interaction of DNAm at C1R with prognostic relevant
mutations, we performed an additional Kaplan-Meier ana-
lysis for patients without the above mentioned mutations.
In this subset of patients, DNAm of C1R was also indica-
tive for OS (P = 0.036; Additional file 1: Figure S10).
Analysis of DNA-methylation at C1R in various other types
of cancer
To estimate if DNAm in C1R might also be a suitable
biomarker for OS in other types of cancer, we utilized
5699 DNAm profiles of 25 different types of tumor from
TCGA. In fact, significant association in COX analysis
was also observed for kidney renal papillary carcinoma
(P = 0.00009), low-grade glioma (P = 0.0002), skin cuta-
neous melanoma (P = 0.002), hepatocellular carcinoma
(P = 0.026), and glioblastoma (P = 0.042; Additional file 1:
Table S5). These results indicate similar association of
DNAm in C1R with OS in other tumors, but the
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prognostic relevance was found to be particularly predom-
inant in patients with AML.
Conclusions
In this study, we demonstrate that DNAm at a single CpG
site in C1R is indicative for overall survival in AML. In
contrast to previously described epigenetic signatures
[3, 7, 18], our method is based on only one CpG site. It
is unclear if C1R plays a functional role for leukemia
development or if it is differentially methylated in leukemia
initiating cells, but this is not a prerequisite for biomarkers.
Our data indicate that DNAm of C1R may reflect global
chromatin reorganization in a subset of AML patients, and
this may contribute to specific genomic mutations or vice
versa [12, 17]. We have demonstrated that DNAm of C1R
was also of prognostic relevance in cytogenetic normal
AMLs, in subsets with defined cytogenetic risk score, and
in subsets without specific genomic mutations. These
results suggest that DNAm in C1R is of independent
prognostic significance, but further validation with larger
datasets is required to ultimately substantiate the clinical
potential. Many cytogenetic aberrations are routinely ana-
lyzed in AML diagnostics, but the importance of epigenetic
biomarkers should not be neglected, considering that AML
develops by means of genetic and epigenetic changes as
well. Complementation of epigenetic biomarkers to exist-
ing genetic biomarkers could provide a balanced and more
accurate diagnostic approach. Furthermore, it is conceiv-
able that DNAm in C1R is also indicative for treatment
response to specific drugs, particularly for demethylating
Fig. 2 DNA-methylation in C1R is associated with clinical parameters. a The CpG site cg08799922 is positioned in a regulatory region in the C1R
gene, with binding sites of the architectural protein CTCF and cohesin components SMC1 and RAD21 in close proximity [20]. b Beta-value range
of 194 AML patients [9] (yellow) and 656 healthy individuals [19] (brown) at 11 CpGs that are associated with C1R. Particularly, our selected CpG
cg08799922 (in 5’UTR; red) and another site cg06915053 (first upstream in TSS200) are associated with OS. c Overall, AML patients [9] with lower
DNAm (<27 % DNAm level) at cg08799922 (C1R) have higher gene expression of C1R. Correlation of DNAm at cg08799922 (C1R) with bone marrow blasts
(d), gender (e), cytogenetic risk (f), and AML FAB-subtype classification (g). *P< 0.01, **P< 0.001, and ***P< 0.0001 by Mann-Whitney test. h Enrichment of
specific mutations according to DNAm level at C1R (P values: hypergeometric distribution)
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agents, and this needs to be addressed in future studies.
Either way, analysis of DNAm at a unique CpG site pro-
vides a very simple and robust biomarker to complement
risk assessment in AML.
Study design
DNAm profiles and bioinformatics analysis
We used publically available DNAm profiles (all based on
HumanMethylation450K BeadChip) of AML patients from
The Cancer Genome Atlas (TCGA) [9] and a study of Qu
et al. (GSE58477) [13], of healthy individuals (GSE40279,
GSE35069) [10, 19], and of 25 other types of cancer
(TCGA). For Kaplan-Meier estimation of overall survival,
we stratified samples by median DNAm levels and adjusted
the results for multiple testing (log-rank test calculated in
R). Alternatively, we calculated COX regression with OS
for each individual CpG site in R.
Blood samples and pyrosequencing
Blood samples were taken from 40 healthy donors and 84
AML patients after written consent according to the
guidelines of the ethics committee of the Medical Faculty
of the RWTH Aachen (Permit Number: EK206/09). Pa-
tient characteristics are summarized in Additional file 1:
Table S6. Genomic DNA was isolated from blood, bisulfite
converted, and analyzed by pyrosequencing (primers are
provided in Additional file 1: Table S7). More detailed
methods are described in the supplemental document.
Availability of supporting data
The data sets supporting the results of this article are
available at The Cancer Genome Atlas portal (https://
tcga-data.nci.nih.gov/tcga/) [9] and at Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the
accession numbers GSE58477 [13], GSE40279 [19], and
GSE35069 [10].
Additional file
Additional file 1: PDF with all supplemental data. This file contains
additional details on methods, Tables S1–S7, and Figures S1–S10. (PDF 1718 kb)
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